Trading of Supernus Pharmaceuticals was halted at 05:06 AM ET due to "News Pending" and resumed at 05:06 AM ET. Trending NewsTrending NewsNASDAQ:SUPN Supernus Pharmaceuticals (SUPN) Stock Price, News & Analysis $28.15 -13.77 (-32.85%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Supernus Pharmaceuticals Stock (NASDAQ:SUPN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SUPN alerts:Sign Up Key Stats Today's Range$27.97▼$31.6250-Day Range$37.88▼$45.3652-Week Range$27.97▼$59.68Volume7.83 million shsAverage Volume815,195 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$62.33Consensus RatingReduce Company Overview Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics. Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older. The company also maintains development programs intended to expand its portfolio of neurological treatments. Founded in 2005 and headquartered in Rockville, Maryland, Supernus primarily serves the U.S. pharmaceutical market through its commercial operations and partnerships. Jack Khattar, who founded the company, serves as its president and chief executive officer. The company’s products are distributed through the U.S. healthcare system, including prescribing physicians, pharmacies, and specialty providers.AI Generated. May Contain Errors. Read More Supernus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreSUPN MarketRank™: 3.300901136215 of 5 starsSupernus Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 297th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingReduce Consensus RatingSupernus Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 2 sell ratings.Upside PotentialSupernus Pharmaceuticals has a consensus price target of $62.33, representing about 118.5% upside from its current price of $28.53.Amount of Analyst CoverageSupernus Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Supernus Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth105.59% Earnings GrowthEarnings for Supernus Pharmaceuticals are expected to grow by 105.59% in the coming year, from $1.79 to $3.68 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Supernus Pharmaceuticals is -37.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Supernus Pharmaceuticals is -37.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioSupernus Pharmaceuticals has a PEG Ratio of 1.21. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioSupernus Pharmaceuticals has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.59% of the float of Supernus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSupernus Pharmaceuticals has a short interest ratio ("days to cover") of 4.93.Change versus previous monthShort interest in Supernus Pharmaceuticals has recently decreased by 18.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSupernus Pharmaceuticals does not currently pay a dividend.Dividend GrowthSupernus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.29 News SentimentSupernus Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Supernus Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest2 people have searched for SUPN on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Supernus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Supernus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders8.50% of the stock of Supernus Pharmaceuticals is held by insiders.Percentage Held by InstitutionsSupernus Pharmaceuticals has minimal institutional ownership at this time.Read more about Supernus Pharmaceuticals' insider trading history. Receive SUPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SUPN Stock News HeadlinesSupernus Completes Merger With Indivior; Creates CNS-Focused BiopharmaNovember 3 at 7:18 AM | rttnews.comIndivior Pharmaceuticals, Inc. completed the acquisition of Supernus Pharmaceuticals, Inc. from group of shareholders in a merger of equals transaction.November 3 at 2:17 AM | marketscreener.comMYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 3 at 1:00 AM | Behind the Markets (Ad)Supernus Pharmaceuticals Completes Merger, Begins Nasdaq Delisting ProcessNovember 2 at 11:51 AM | tipranks.comSupernus Pharmaceuticals Completes Merger with Indivior PharmaceuticalsNovember 2 at 10:11 AM | tipranks.comIndivior Completes Merger with Supernus, Expanding CNS PortfolioNovember 2 at 10:11 AM | tipranks.comSupernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical LeaderNovember 2 at 9:18 AM | globenewswire.comComparing Supernus Pharmaceuticals (NASDAQ:SUPN) & Assembly Biosciences (NASDAQ:ASMB)November 2 at 3:23 AM | americanbankingnews.comSee More Headlines SUPN Stock Analysis - Frequently Asked Questions How have SUPN shares performed this year? Supernus Pharmaceuticals' stock was trading at $49.70 at the beginning of the year. Since then, SUPN shares have decreased by 42.6% and is now trading at $28.53. How were Supernus Pharmaceuticals' earnings last quarter? Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its quarterly earnings data on Thursday, October, 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by $0.14. The firm's revenue for the quarter was up 18.0% on a year-over-year basis. Read the conference call transcript. When did Supernus Pharmaceuticals IPO? Supernus Pharmaceuticals (SUPN) raised $75 million in an initial public offering (IPO) on Tuesday, May 1st 2012. The company issued 5,769,000 shares at a price of $12.00-$14.00 per share. Who are Supernus Pharmaceuticals' major shareholders? Supernus Pharmaceuticals' top institutional investors include Pictet Asset Management Holding SA (0.75%), Signaturefd LLC (0.11%), Profund Advisors LLC (0.07%) and James Investment Research Inc. (0.04%). Insiders that own company stock include Jack A Khattar, Tami Tillotson Martin, Frederick M Hudson, Georges Gemayel, Padmanabh P Bhatt, Frank Mottola, Jonathan Rubin, Timothy C Dec and Bethany Sensenig. View institutional ownership trends. How do I buy shares of Supernus Pharmaceuticals? Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Supernus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Supernus Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Block (XYZ), Netflix (NFLX) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings10/29/2026Record date for 11/6 Dividend10/30/2026Today11/03/2026Dividend Payable11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SUPN's financial health is in the Red zone, according to TradeSmith. SUPN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SUPN CIK1356576 Webwww.supernus.com Phone(301) 838-2500Fax301-838-2501Employees778Year Founded2005Price Target and Rating Average Price Target for Supernus Pharmaceuticals$62.33 High Price Target$67.00 Low Price Target$55.00 Potential Upside/Downside+121.4%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E Ratio7.65 P/E Growth1.21Net Income-$38.55 million Net Margins-13.23% Pretax Margin-14.87% Return on Equity11.13% Return on Assets8.10% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio1.84 Sales & Book Value Annual Sales$718.95 million Price / Sales2.28 Cash Flow$2.59 per share Price / Cash Flow10.88 Book Value$18.52 per share Price / Book1.52Miscellaneous Outstanding Shares58,220,000Free Float53,286,000Market Cap$1.64 billion OptionableOptionable Beta0.55 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:SUPN) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SUPN Stock Alerts